Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from ThermoFisher Scientific.

Community Practice Connections™: Precision Medicine in Oncology: Current Role and Future Potential of In-House NGS Technologies

Release Date: January 6, 2020
Expiration Date: January 6, 2021
Media: Internet - based

Activity Overview

Next-generation sequencing (NGS) is a widely used instrument in the field of adult hematology/oncology. However, key differences between pediatric and adult cancers at the genetic level limit the utility of the most well-established NGS panels for pediatric cancer testing. With the emergence of pediatric-tumor–specific testing assays, it is important for clinicians to remain up to date on the latest technologies to ensure that their patients with childhood cancers receive the best possible care. This activity will provide you with an overview of the history of NGS in cancer care and its developing role in pediatric hematology/oncology; the rationales for the different testing platforms, along with their utility, strengths, and limitations; and a critical evaluation of data supporting clinical application of established biomarkers in a variety of pediatric cancers.

Click to view slides from the live conference Precision Medicine in Oncology: Current Role and Future Potential of In-House NGS Technologies

Benefits of Participating

  • Learn the latest information regarding the optimal use of NGS in pediatric cancer, including the specific ways it can contribute to diagnosis and treatment
  • Compare and contrast current and emerging NGS technologies
  • Learn from case studies how the use of NGS can be applied in a variety of different malignancies
  • Hear expert perspectives on where this field is headed and how it may benefit patients now and in the future

Acknowledgement of Commercial Support

This activity is supported by an educational grant from ThermoFisher Scientific.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • To receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with cancer. Surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Outline the clinical implications of next-generation sequencing (NGS) for pediatric and young adult patients with cancer.
  • Develop evidence-based strategies to individualize treatment of pediatric and young adult patients with cancer based on assessment of tumor profile and patient characteristics.
  • Identify the role of multidisciplinary teams to facilitate, interpret, and implement novel in-house NGS technologies in clinical practice.
  • Assess methods to overcome barriers to facilitate the use of NGS strategies for pediatric and young adult patients in community settings.

Faculty, Staff, and Planners’ Disclosures

Chair

Timothy Triche
Timothy Triche, MD, PhD
Professor of Pathology and Pediatrics
Keck School of Medicine of the University of Southern California
Co-Director, Center for Personalized Medicine
Children’s Hospital Los Angeles
Los Angeles, CA

Disclosures: no relevant financial relationships with commercial interests.

Faculty

Jaclyn Biegel
Jaclyn Biegel, PhD
Director and Division Chief of Genomic Medicine
Center for Personalized Medicine
Children’s Hospital Los Angeles
Professor of Pathology (Clinical Scholar)
Keck School of Medicine of the University of Southern California
Los Angeles, CA

Disclosures: no relevant financial relationships with commercial interests.

Leo Mascarenhas
Leo Mascarenhas, MD, MS
Deputy Director, Cancer and Blood Disease Institute
Section Head, Oncology
Children’s Hospital Los Angeles
Associate Professor of Clinical Pediatrics
Keck School of Medicine of the University of Southern California
Los Angeles, CA

Disclosures: Grant Research Support: AstraZeneca; Consultant: Bayer, Eli Lilly, AstraZeneca; Speakers Bureau: Bayer; Other: AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Incyte Corporation, Jazz Pharmaceuticals, Pfizer.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, PER® makes it a policy to ensure fair balance, independence, objectivity, and scientific rigor in all its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for CME purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By